Further Studies on the Skin Erythema with Combinations of Two Types of Radiation

Radiology ◽  
1930 ◽  
Vol 15 (1) ◽  
pp. 30-41 ◽  
Author(s):  
Edith H. Quimby ◽  
George T. Pack
Keyword(s):  
Skin Erythema

Quantitative assessment of skin erythema due to radiotherapy—evaluation of different measurements

2004 ◽  
Vol 72 (2) ◽  
pp. 191-197 ◽  
Author(s):  
Yvonne Wengström ◽  
Christina Forsberg ◽  
Ingemar Näslund ◽  
Jonas Bergh
Keyword(s):  
Quantitative Assessment ◽  
Skin Erythema

Utility of Inflammatory Markers in Hospitalized Children With Skin Erythema

2021 ◽  
Vol 11 (6) ◽  
pp. 627-631
Author(s):  
Beth D. Harper ◽  
Carolyn H. Marcus ◽  
Natalie Burke ◽  
Kosuke Kawai ◽  
Jonathan M. Mansbach
Keyword(s):  
Inflammatory Markers ◽  
Hospitalized Children ◽  
Skin Erythema

Dermatology

2020 ◽  
pp. 559-616
Author(s):  
Chantal Simon ◽  
Hazel Everitt ◽  
Françoise van Dorp ◽  
Nazia Hussain ◽  
Emma Nash ◽  
...  
Keyword(s):  
General Practice ◽  
Skin Cancer ◽  
Fungal Infection ◽  
Sweat Gland ◽  
Skin Infection ◽  
Skin Tumours ◽  
Nail Changes ◽  
Skin Erythema ◽  
Keratinization Disorders ◽  
Skin Conditions

This chapter in the Oxford Handbook of General Practice explores dermatology in general practice. It covers skin assessment, treatment of skin conditions, changes in skin colour and eruptions, itching and blistering of the skin, erythema, pigmentation disorder, hair and sweat gland problems, nail changes, and atopic and other eczemas. It discusses ulcers, urticaria, angio-oedema, acne, psoriasis, lichen planus, keratinization disorders, pityriasis, and seborrhoeic warts. It examines sunlight and the skin, benign skin tumours, and skin cancer. It also explores bacterial skin infection, viral skin infection, fungal infection, and infestation.

Quantitative and Qualitative Evaluation of Skin Erythema

Radiology ◽  
1960 ◽  
Vol 75 (3) ◽  
pp. 411-415 ◽  
Author(s):  
Arvin S. Glicksman ◽  
Florence C. H. Chu ◽  
Harry N. Bane ◽  
James J. Nickson
Keyword(s):  
Qualitative Evaluation ◽  
Skin Erythema

scholarly journals Topical Nanofat Biocrème Improves Aesthetic Outcomes of Nonablative Fractionated Laser Treatment: A Preliminary Report

2019 ◽  
Vol 40 (8) ◽  
pp. 892-899 ◽  
Author(s):  
Steven R Cohen ◽  
Ashley K Goodacre ◽  
Hayley Womack ◽  
Flore Delaunay ◽  
Danielle Wood ◽  
...  
Keyword(s):  
Platelet Rich Plasma ◽  
Nasolabial Fold ◽  
Laser Resurfacing ◽  
Delivery Vector ◽  
Before And After ◽  
Skin Erythema ◽  
Historical Group ◽  
Skin Biopsies ◽  
Nasolabial Folds ◽  
Histologic Changes

Abstract Background Improvements in skin erythema and elasticity have been observed with topical application of platelet-rich plasma after fractional laser (FXD) treatment. Injections of nanofat via small needles into the dermis improves tissue thickness, discoloration and wrinkle depth. Objectives The aim of this study was to evaluate improvements in skin following a nonablative FXD treatment combined with the application of a novel topical nanofat biocrème, called neo-U. Methods Fifty patients were treated with a nonablative FXD followed by application of a topical nanofat biocrème. Harvested fat was processed into nanofat, which was compounded with a transdermal liposomal delivery vector to produce a topical biocrème. In 2 patients, postauricular skin punch biopsies were performed before and after treatment and examined for histologic changes. Photographs of a historical group treated with only the FXD were compared with photographs of patients treated with a combination of topical nanofat biocrème and FXD. Skin types were evaluated for improvements in nasolabial folds, wrinkles, and skin texture. Results Findings from postauricular skin biopsies show the skin exposed to FXD with nanofat biocrème had more elastin fibers and a slight increase in the thickness of the epidermis. Patients treated with FXD plus nanofat biocrème had a statistically significant improvement in the degree of wrinkles, nasolabial fold depth, and texture compared with historical controls. Conclusions Transdermal delivery of nanofat topical biocrème applied after FXD treatment can serve as a delivery system to improve fine lines, nasolabial fold depth, and overall texture of the tissue to a greater degree than laser resurfacing alone.

scholarly journals P420 A randomised, observer-blinded phase Ib multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S382-S383 ◽  
Author(s):  
F Wagner ◽  
J Mansfield ◽  
C Geier ◽  
A Dash ◽  
Y Wang ◽  
...  
Keyword(s):  
Adverse Events ◽  
Fusion Protein ◽  
Healthy Volunteers ◽  
Drug Clearance ◽  
Multiple Time ◽  
Dry Skin ◽  
Serious Adverse Events ◽  
Mucin Production ◽  
Interleukin 22 ◽  
Skin Erythema

Abstract Background Inflammatory bowel disease (IBD) is characterised by gut dysbiosis, weakened epithelial barrier, and a dysregulated immune system. Interleukin-22 (IL-22), an IL-10 family cytokine, has demonstrated efficacy in animal IBD models by promoting intestinal epithelial repair, increasing antimicrobial peptide production, and increasing mucin production via goblet cells1. UTTR1147A is a fusion protein in which IL-22 is linked with the Fc portion of IgG4 to improve the pharmacokinetic (PK) characteristics. Methods A phase I study (NCT02749630) was conducted to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of repeat IV dosing of UTTR1147A in healthy volunteers (HV) and UC patients with centrally read Mayo endoscopic score ≥ 2. 38 HVs and 24 UC patients were given UTTR1147A or placebo at doses ranging from 30 to 90 µg/kg either biweekly or monthly (6:2 UTTR1147A: placebo per cohort). PK and serum PD (REG3A and CRP) were studied across multiple time points and the Mayo Clinic Score was evaluated at baseline, day 30 and day 85. Results Overall, UTTR1147A was safe and adequately tolerated in HV and UC patients. The most common adverse events were on-target dermatological effects (dry skin, erythema, and pruritus) that were manageable, monitorable and reversible. Dose-limiting non-serious dermatological toxicities (severe dry skin, erythema, exfoliation, and discomfort) were seen in two HVs and 1 UC patient dosed with 90ug/kg Q2wk. There were 2 unrelated serious adverse events (ankle fracture and cytomegalovirus infection) that eventually resolved. PK analyses showed that UTTR1147A exposures were, in general, dose proportional within HVs and within UC patients, with a mean elimination half-life of ~16 days and ~12 days, respectively. At the same dose level, UC patients showed relatively lower drug exposures than HVs, possibly due to faster drug clearance. Consistent with the Phase Ia2, UTTR1147A directly induced production of serum PD biomarkers REG3A and CRP at all dose cohorts tested compared with placebo. Notably, UC patients appear to have attenuated serum PD responses compared with HV. Clinical response was observed in 7/18 patients, and clinical remission in 5/18 patients treated with UTTR1147A compared with 1/6 and 0/6 placebo patients, respectively. Conclusion UTTR1147A demonstrated adequate safety and PK profile in healthy volunteers and UC patients. PD biomarker data demonstrated pharmacological activity of UTTR1147A providing evidence of IL-22R pathway activation. Together with the preliminary signals of efficacy, these data support further investigation of this potential, novel non-immunosuppressive therapy in IBD.

A 12-Year Single-Institution Experience with Accelerated Partial Breast Irradiation

2018 ◽  
Vol 84 (8) ◽  
pp. 1261-1263
Author(s):  
Anthony M. Scott ◽  
Matthew C. Callier ◽  
Madison Lashley ◽  
David A. Cole ◽  
Paul S. Dale
Keyword(s):  
Skin Irritation ◽  
Breast Conserving Surgery ◽  
Accelerated Partial Breast Irradiation ◽  
Partial Breast Irradiation ◽  
Breast Irradiation ◽  
Single Institution ◽  
Recurrence Rates ◽  
Breast Brachytherapy ◽  
Skin Erythema ◽  
American Society

Accelerated partial breast irradiation (APBI) using the implanted brachytherapy device MammoSite® was approved for routine use by the Food and Drug Administration in 2002. The American Society of Breast Surgeons MammoSite® Breast Brachytherapy Registry served as a guideline for our institution to begin offering this treatment in 2005. This report reviews our available data to provide an analysis of patient outcomes over 12 years of use at a single institution. A retrospective review was conducted of records of 150 patients who underwent APBI or attempted APBI after breast-sparing surgeries between 2006 and 2017. These charts were analyzed for documentation of patient age, cancer stage, incidence of recurrence, and posttreatment complications. Of the patients evaluated, 99 per cent (149/150) completed treatment. The median time since treatment completion is now 8.9 years. One hundred eleven patients (74%) are now greater than five years posttreatment. Ipsilateral breast recurrence was found in 2.7 per cent of patients (4/149), and 1.3 per cent of patients (2/149) developed new primary breast tumors. Acute complications, mostly skin erythema (21%), were uncommon and self-limited. Subacute effects were generally fibrosis (13%) and mild local pain (9.4%). APBI for breast cancer after breast-conserving surgery continues to be used at our institution for select patients with good outcomes. Local control and toxicity are similar to that reported in the literature. Five-year local recurrence rates compare favorably with national trials. Occasional complications included fibrosis, persistent pain, and skin irritation.

Sign in / Sign up

Export Citation Format

Share Document